nach oben

Erschienen in:

04.07.2018 | Review Article

Neoadjuvant chemotherapy for breast cancer—background for the indication of locoregional treatment

verfasst von: David Krug, René Baumann, Wilfried Budach, Jürgen Dunst, Petra Feyer, Rainer Fietkau, Wulf Haase, Wolfgang Harms, Thomas Hehr, Marc D. Piroth, Felix Sedlmayer, Rainer Souchon, Frederik Wenz, Rolf Sauer, Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO)

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

Neoadjuvant chemotherapy (NACT) has been widely adopted into the multidisciplinary management of breast cancer. The prognostic impact of treatment response has been clearly demonstrated. However, the impact of treatment response on the indication for adjuvant radiotherapy is unclear. This review summarizes important implications of NACT and treatment response on the risk of recurrence and locoregional multidisciplinary management from the standpoint of radiation oncology.

Wenz F, Budach W (2017) Personalized radiotherapy for invasive breast cancer in 2017: National S3 guidelines and DEGRO and AGO recommendations. Strahlenther Onkol 193:601–603. https://doi.org/10.1007/s00066-017-1158-1 CrossRefPubMed

Krug D, Baumann R, Budach W et al (2018) Individualization of post-mastectomy radiotherapy and regional nodal irradiation based on treatment response after neoadjuvant chemotherapy for breast cancer: a systematic review. Strahlenther Onkol 194:607–618. https://doi.org/10.1007/s00066-018-1270-x CrossRefPubMed

Kaufmann M, von Minckwitz G, Mamounas EP et al (2011) Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 19:1508–1516. https://doi.org/10.1245/s10434-011-2108-2 CrossRefPubMed

Liedtke C, Thill M, on behalf of the AGO Breast Committee (2016) AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2016. Breast Care 11:204–214. https://doi.org/10.1159/000446941 CrossRefPubMedPubMedCentral

Groheux D, Moretti J‑L, Baillet G et al (2008) Effect of (18)F-FDG PET/CT imaging in patients with clinical stage II and III breast cancer. Int J Radiat Oncol Biol Phys 71:695–704. https://doi.org/10.1016/j.ijrobp.2008.02.056 CrossRefPubMed

Koolen BB, Valdés Olmos RA, Vogel WV et al (2013) Pre-chemotherapy 18 F-FDG PET/CT upstages nodal stage in stage II–III breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 141:249–254. https://doi.org/10.1007/s10549-013-2678-8 CrossRefPubMed

Ng SP, David S, Alamgeer M, Ganju V (2015) Impact of pretreatment combined (18)F-Fluorodeoxyglucose positron emission tomography/computed tomography staging on radiation therapy treatment decisions in locally advanced breast cancer. Int J Radiat Oncol Biol Phys 93:111–117. https://doi.org/10.1016/j.ijrobp.2015.05.012 CrossRefPubMed

Lyman GH, Temin S, Edge SB et al (2014) Sentinel lymph node biopsy for patients with early-stage breast cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol 32:1365–1383. https://doi.org/10.1200/JCO.2013.54.1177 CrossRefPubMed

Zetterlund L, Celebioglu F, Axelsson R et al (2017) Swedish prospective multicenter trial on the accuracy and clinical relevance of sentinel lymph node biopsy before neoadjuvant systemic therapy in breast cancer. Breast Cancer Res Treat 163:93–101. https://doi.org/10.1007/s10549-017-4163-2 CrossRefPubMedPubMedCentral

10.

Garcia-Tejedor A, Falo C, Quetglas C et al (2017) Feasibility, accuracy and prognosis of sentinel lymph node biopsy before neoadjuvant therapy in breast cancer. A prospective study. Int J Surg 39:141–147. https://doi.org/10.1016/j.ijsu.2017.01.106 CrossRefPubMed

11.

Tadros AB, Yang WT, Krishnamurthy S et al (2017) Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg. https://doi.org/10.1001/jamasurg.2017.0562 PubMedPubMedCentralCrossRef

12.

Boileau JF, Poirier B, Basik M et al (2015) Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol 33:258–264. https://doi.org/10.1200/JCO.2014.55.7827 CrossRefPubMed

13.

Boughey JC (2013) Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer. JAMA 310:1455–1457. https://doi.org/10.1001/jama.2013.278932 CrossRefPubMedPubMedCentral

14.

Kuehn T, Bauerfeind I, Fehm T et al (2013) Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 14:609–618. https://doi.org/10.1016/S1470-2045(13)70166-9 CrossRefPubMed

15.

Caudle AS, Yang WT, Krishnamurthy S et al (2016) Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 34:1072–1078. https://doi.org/10.1200/JCO.2015.64.0094 CrossRefPubMedPubMedCentral

16.

Donker M, Straver ME, Wesseling J et al (2015) Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients. Ann Surg 261:378–382. https://doi.org/10.1097/SLA.0000000000000558 CrossRefPubMed

17.

Galimberti V, Fontana SKR, Maisonneuve P et al (2016) Sentinel node biopsy after neoadjuvant treatment in breast cancer: five-year follow-up of patients with clinically node-negative or node-positive disease before treatment. Eur J Surg Oncol 42:361–368. https://doi.org/10.1016/j.ejso.2015.11.019 CrossRefPubMed

18.

Nogi H, Uchida K, Mimoto R et al (2017) Long-term follow-up of node-negative breast cancer patients evaluated via sentinel node biopsy after neoadjuvant chemotherapy. Clin Breast Cancer. https://doi.org/10.1016/j.clbc.2017.05.002 PubMedCrossRef

19.

Cortazar P, Zhang L, Untch M et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164–172. https://doi.org/10.1016/S0140-6736(13)62422-8 CrossRefPubMed

20.

von Minckwitz G, Untch M, Nüesch E et al (2010) Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 125:145–156. https://doi.org/10.1007/s10549-010-1228-x CrossRef

21.

Schneeweiss A, Möbus V, Tesch H et al (2017) A randomised phase III trial comparing two dose-dense, dose-intensified approaches (ETC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto). J Clin Oncol 35:abstr 518CrossRef

22.

Berruti A, Amoroso V, Gallo F et al (2014) Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. J Clin Oncol 32:3883–3891. https://doi.org/10.1200/JCO.2014.55.2836 CrossRefPubMed

23.

Symmans WF, Peintinger F, Hatzis C et al (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414–4422. https://doi.org/10.1200/JCO.2007.10.6823 CrossRefPubMed

24.

Symmans WF, Wei C, Gould R et al (2017) Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol 35:1049–1060. https://doi.org/10.1200/JCO.2015.63.1010 CrossRefPubMedPubMedCentral

25.

Mougalian SS, Hernandez M, Lei X et al (2016) Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy. JAMA Oncol 2:508–518. https://doi.org/10.1001/jamaoncol.2015.4935 CrossRefPubMedPubMedCentral

26.

Jeruss JS, Mittendorf EA, Tucker SL et al (2008) Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol 26:246–252. https://doi.org/10.1200/JCO.2007.11.5352 CrossRefPubMed

27.

Mittendorf EA, Jeruss JS, Tucker SL et al (2011) Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with Neoadjuvant chemotherapy. J Clin Oncol 29:1956–1962. https://doi.org/10.1200/JCO.2010.31.8469 CrossRefPubMedPubMedCentral

28.

Mittendorf EA, Vila J, Tucker SL et al (2016) The neo-bioscore update for staging breast cancer treated with Neoadjuvant chemotherapy: incorporation of prognostic biologic factors into staging after treatment. JAMA Oncol 2:929–936. https://doi.org/10.1001/jamaoncol.2015.6478 CrossRefPubMedPubMedCentral

29.

Marmé F, Lederer B, Blohmer J‑U et al (2016) Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2‑negative breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 53:65–74. https://doi.org/10.1016/j.ejca.2015.09.022 CrossRefPubMed

30.

Mauri D, Pavlidis N, Ioannidis JPA (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97:188–194. https://doi.org/10.1093/jnci/dji021 CrossRefPubMed

31.

Mieog JSD, van der Hage JA, van de Velde CJH (2007) Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 94:1189–1200. https://doi.org/10.1002/bjs.5894 CrossRefPubMed

32.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2018) Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol 19:27–39. https://doi.org/10.1016/S1470-2045(17)30777-5 CrossRef

33.

Mittendorf EA, Buchholz TA, Tucker SL et al (2013) Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy. Ann Surg 257:173–179. https://doi.org/10.1097/SLA.0b013e3182805c4a CrossRefPubMedPubMedCentral

34.

Mamounas EP, Anderson SJ, Dignam JJ et al (2012) Predictors of Locoregional recurrence after Neoadjuvant chemotherapy: results from combined analysis of national surgical adjuvant breast and bowel project B‑18 and B‑27. J Clin Oncol 30:3960–3966. https://doi.org/10.1200/JCO.2011.40.8369 CrossRefPubMedPubMedCentral

35.

Mamounas EP, Cortazar P, Zhang L et al (2014) Locoregional Recurrence (LRR) after Neoadjuvant Chemotherapy (NAC): pooled-analysis results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC). J Clin Oncol 32:61–61. https://doi.org/10.1200/jco.2014.32.26_suppl.61 CrossRef

36.

Cureton EL, Yau C, Alvarado MD et al (2014) Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I‑SPY 1 trial (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol 21:2889–2896. https://doi.org/10.1245/s10434-014-3721-7 CrossRefPubMedPubMedCentral

37.

Haffty BG, Ballman KV, Hunt KK et al (2016) Impact of radiation on local regional control in women with node-positive breast cancer treated with Neoadjuvant chemotherapy (NAC) and axillary lymph node dissection (ALND); results from ACOSOG Z1071 (alliance). Int J Radiat Oncol Biol Phys 96:S144. https://doi.org/10.1016/j.ijrobp.2016.06.350 CrossRef

38.

Gillon P, Touati N, Breton-Callu C et al (2017) Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: an analysis of the EORTC 10994/BIG 1‑00 study. Eur J Cancer 79:226–234. https://doi.org/10.1016/j.ejca.2017.04.012 CrossRefPubMed

39.

Caudle AS, Yu T‑K, Tucker SL et al (2012) Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res 14:R83. https://doi.org/10.1186/bcr3198 CrossRefPubMedPubMedCentral

40.

Swisher SK, Vila J, Tucker SL et al (2016) Locoregional control according to breast cancer subtype and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast-conserving therapy. Ann Surg Oncol 23:749–756. https://doi.org/10.1245/s10434-015-4921-5 CrossRefPubMed

41.

Vila J, Teshome M, Tucker SL et al (2017) Combining clinical and pathologic staging variables has prognostic value in predicting local-regional recurrence following neoadjuvant chemotherapy for breast cancer. Ann Surg 265:574–580. https://doi.org/10.1097/SLA.0000000000001492 CrossRefPubMed

Titel: Neoadjuvant chemotherapy for breast cancer—background for the indication of locoregional treatment
verfasst von: David Krug
René Baumann
Wilfried Budach
Jürgen Dunst
Petra Feyer
Rainer Fietkau
Wulf Haase
Wolfgang Harms
Thomas Hehr
Marc D. Piroth
Felix Sedlmayer
Rainer Souchon
Frederik Wenz
Rolf Sauer
Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO)
Publikationsdatum: 04.07.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 9/2018
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-018-1329-8

Neu im Fachgebiet Onkologie

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Neoadjuvant chemotherapy for breast cancer—background for the indication of locoregional treatment

Abstract

Neu im Fachgebiet Onkologie

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

Das sind die führenden Symptome junger Darmkrebspatienten

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2018

Non-coplanar VMAT combined with non-uniform dose prescription markedly reduces lung dose in breath-hold lung SBRT

Treatment planning for spinal radiosurgery

Linac-based stereotactic body radiation therapy for unresectable locally advanced pancreatic cancer: risk-adapted dose prescription and image-guided delivery

Einsatz alternativer Behandlungsmethoden bei Krebserkrankungen und Auswirkungen auf das Überleben

Stellenwert der stereotaktischen Radiotherapie für das nichtresezierte Pankreaskarzinom

Neoadjuvante Chemotherapie vor radikaler Hysterektomie beim Zervixkarzinom – Response ist nicht Überleben

Neu im Fachgebiet Onkologie

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

Das sind die führenden Symptome junger Darmkrebspatienten

Update Onkologie